Follow
Michele Moschetta, MD PhD
Michele Moschetta, MD PhD
Clinical Program Leader at Novartis Institutes for BioMedical Research (NIBR)
Verified email at novartis.com
Title
Cited by
Cited by
Year
Targeting the bone marrow microenvironment in multiple myeloma
Y Kawano, M Moschetta, S Manier, S Glavey, GT GŲrgŁn, AM Roccaro, ...
Immunological reviews 263 (1), 160-172, 2015
3382015
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
YT Tai, C Acharya, G An, M Moschetta, MY Zhong, X Feng, M Cea, ...
Blood, The Journal of the American Society of Hematology 127 (25), 3225-3236, 2016
2672016
Engineered nanomedicine for myeloma and bone microenvironment targeting
A Swami, MR Reagan, P Basto, Y Mishima, N Kamaly, S Glavey, S Zhang, ...
Proceedings of the National Academy of Sciences 111 (28), 10287-10292, 2014
2672014
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
M Moschetta, A George, SB Kaye, S Banerjee
Annals of Oncology 27 (8), 1449-1455, 2016
2382016
Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple MyelomaMetabolomic Signature and Drug Resistance in Multiple Myeloma
P Maiso, D Huynh, M Moschetta, A Sacco, Y Aljawai, Y Mishima, ...
Cancer research 75 (10), 2071-2082, 2015
2242015
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
AM Roccaro, A Sacco, C Jimenez, P Maiso, M Moschetta, Y Mishima, ...
Blood, The Journal of the American Society of Hematology 123 (26), 4120-4131, 2014
2112014
SDF-1 inhibition targets the bone marrow niche for cancer therapy
AM Roccaro, A Sacco, WG Purschke, M Moschetta, K Buchner, C Maasch, ...
Cell reports 9 (1), 118-128, 2014
1482014
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation
AM Roccaro, Y Mishima, A Sacco, M Moschetta, YT Tai, J Shi, Y Zhang, ...
Cell reports 12 (4), 622-635, 2015
1262015
Therapeutic targeting of the mTOR‐signalling pathway in cancer: benefits and limitations
M Moschetta, A Reale, C Marasco, A Vacca, MR Carratý
British journal of pharmacology 171 (16), 3801-3813, 2014
1212014
Role of endothelial progenitor cells in cancer progression
M Moschetta, Y Mishima, I Sahin, S Manier, S Glavey, A Vacca, ...
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (1), 26-39, 2014
1192014
The cancer glycome: carbohydrates as mediators of metastasis
SV Glavey, D Huynh, MR Reagan, S Manier, M Moschetta, Y Kawano, ...
Blood reviews 29 (4), 269-279, 2015
1142015
The developing story of predictive biomarkers in colorectal cancer
S Boussios, MA Ozturk, M Moschetta, A Karathanasi, ...
Journal of personalized medicine 9 (1), 12, 2019
1082019
The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma
SV Glavey, S Manier, A Natoni, A Sacco, M Moschetta, MR Reagan, ...
Blood, The Journal of the American Society of Hematology 124 (11), 1765-1776, 2014
1072014
Combined strategies with poly (ADP-Ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review
S Boussios, P Karihtala, M Moschetta, A Karathanasi, A Sadauskaite, ...
Diagnostics 9 (3), 87, 2019
1062019
Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin–Positive Metastatic Human Melanoma XenograftsPaclitaxel with F8-IL2 Immunocytokine†…
M Moschetta, F Pretto, A Berndt, K Galler, P Richter, A Bassi, P Oliva, ...
Cancer research 72 (7), 1814-1824, 2012
1052012
Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
MA Frassanito, L Rao, M Moschetta, R Ria, L Di Marzo, A De Luisi, ...
Leukemia 28 (4), 904-916, 2014
1002014
Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple MyelomaAntiangiogenic Power of Lenalidomide in MM
A De Luisi, A Ferrucci, AML Coluccia, R Ria, M Moschetta, E De Luca, ...
Clinical Cancer Research 17 (7), 1935-1946, 2011
852011
Poly (ADP-Ribose) polymerase inhibitors: talazoparib in ovarian cancer and beyond
S Boussios, C Abson, M Moschetta, E Rassy, A Karathanasi, T Bhat, ...
Drugs in R&D 20, 55-73, 2020
842020
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach
S Boussios, P Karihtala, M Moschetta, C Abson, A Karathanasi, ...
Investigational new drugs 38, 181-193, 2020
772020
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma
M Moschetta, G Di Pietro, R Ria, A Gnoni, G Mangialardi, A Guarini, ...
European Journal of Cancer 46 (2), 420-429, 2010
772010
The system can't perform the operation now. Try again later.
Articles 1–20